GlassScriptPhysician profile
Amanda Marie Curry
NPI 1447594924
$2,474.32
in general payments reported to CMS, 2019-2025
28 companies · $952 in 2025
The $952 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.05 · 2023: $753 · 2024: $754 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,459.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $520.74 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $351.37 | 2023-2025 | |
| Abbvie INC. | $272.61 | 2023-2025 | |
| Lilly USA, LLC | $147.99 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $144.87 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $121.57 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.84 | 2023-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $115.57 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $83.98 | 2025 | Airsupra, Farxiga |
| Boston Scientific Corporation | $69.54 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.27 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $61.14 | 2023 | Vaxneuvance, Gardasil 9, Pneumovax 23 |
| Bayer Healthcare Pharmaceuticals INC. | $48.07 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.07 | 2023-2024 | Jardiance |
| Axsome Therapeutics, INC. | $38.67 | 2023-2024 | Sunosi, Auvelity |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microtransponder, INC. | $33.88 | 2024 | |
| Insulet Corporation | $32.60 | 2025 | Omnipod |
| Inspire Medical Systems, INC. | $28.75 | 2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $23.03 | 2024 | Voquezna |
| Esperion Therapeutics, INC. | $22.39 | 2025 | Nexletol |
| Idorsia Pharmaceuticals US INC | $21.00 | 2023 | Quviviq |
| Optinose US, INC. | $20.80 | 2025 | |
| Neos Therapeutics, LP | $18.74 | 2024 | Adzenys Xr-Odt |
| Resmed Corp | $15.89 | 2025 | |
| Dexcom, INC. | $15.28 | 2025 | Dexcom G6 Transmitter |
| Tris Pharma INC | $15.05 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.04 | 2025 | Trintellix |
| Globus Medical, INC. | $13.57 | 2025 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Curry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.